Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer

Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
Author: Raymond M. Reilly
Publisher: John Wiley & Sons
Total Pages: 849
Release: 2010-12-28
Genre: Science
ISBN: 1118035151

Oncology Book of 2011, British Medical Association's Medical Book Awards Awarded first prize in the Oncology category at the 2011 BMA Medical Book Awards, Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer helps readers understand this hot pharmaceutical field with up-to-date developments. Expert discussion covers a range of diverse topics associated with this field, including the optimization of design of biomolecules and radiochemistry, cell and animal models for preclinical evaluation, discoveries from key clinical trials, radiation biology and dosimetry, and considerations in regulatory approval. With chapters authored by internationally renowned experts, this book delivers a wealth of information to push future discovery.

Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer

Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
Author: Melpomeni Fani
Publisher:
Total Pages: 0
Release: 2012
Genre:
ISBN:

Abstract: Human cancer cells overexpress many peptide receptors as molecular targets. Radiolabeled peptides that bind with high affinity and specificity to the receptors on tumor cells hold great potential for both diagnostic imaging and targeted radionuclide therapy. The advantage of solid-phase peptide synthesis, the availability of different chelating agents and prosthetic groups and bioconjugation techniques permit the facile preparation of a wide variety of peptide-based targeting molecules with diverse biological and tumor targeting properties. Some of these peptides, including somatostatin, bombesin, vasoactive intestinal peptide, gastrin, neurotensin, exendin and RGD are currently under investigation. It is anticipated that in the near future many of these peptides may find applications in nuclear oncology. This article presents recent developments in the field of small peptides, and their applications in the diagnosis and treatment of cancer

Somatostatin Analogues

Somatostatin Analogues
Author: Alicja Hubalewska-Dydejczyk
Publisher: John Wiley & Sons
Total Pages: 379
Release: 2015-06-11
Genre: Science
ISBN: 111903163X

Featuring chapters from specialists in endocrinology, physiology, pathology, and nuclear medicine, this book provides a multidisciplinary approach to a wide variety of issues concerning somatostatin and its analogues. The book: Provides the most up-to-date coverage of somatostatin analog use in diagnostic and therapy Integrating the specialties of endocrinology, physiology, pathology, and nuclear medicine, providing the multidisciplinary approach to the topic Focuses on future applications, novel compounds, and areas for further research Covers topics by authors who are renowned experts and researchers in the field

Optimization of the Solid-phase Synthesis of [18F]-radiolabeled Peptides for Positron Emission Tomography

Optimization of the Solid-phase Synthesis of [18F]-radiolabeled Peptides for Positron Emission Tomography
Author: Jason Bradley White
Publisher:
Total Pages:
Release: 2011
Genre:
ISBN: 9781124908823

The use of peptides for the early detection and treatment of biological malignancies has had a profound effect on the field of molecular imaging. Due in part to their small size, rapid targeting, and relative ease to synthesize, peptides are ideal candidates for radiolabeling using short-lived isotopes such as 18F to provide in vivo visualization of the biomarker of interest using positron emission tomography (PET). The pioneering work of Bruce Merrifield to develop solid-phase peptide synthesis (SPPS) has facilitated the preparation of high-purity peptides and emerged as the methodology of choice for the rapid synthesis and site-specific radiolabeling of peptides for in vivo imaging. We have previously utilized this approach to synthesize and radiolabel the 20 amino acid peptide [18F]FBA-PEG2-A20FMDV2, a selective radiotracer derived from the foot and mouth disease virus (FMDV) that targets the cancer-related [alpha subscipt v][beta]6 integrin. Though this work demonstrated, among other benefits, the successful use of SPPS for the development of peptide-based molecular probes, it did not assess the affects of the solid support (resin) on crude peptide purity, radiochemical yields, and radiolabeling efficiency. Therefore, the aim of this work was to develop a generic platform that not only facilitates the selection of resins with optimal qualities for SPPS, but also identifies solid supports that can be utilized to facilitate the rapid, reliable construction of high-purity radiolabeled peptides for in vivo imaging with PET. To develop this platform, ten representative solid supports (resins) were chosen (amides n = 4, acids n = 3, alcohols n = 3) and analyzed based on several parameters including swelling capacity, SPPS performance, and radiochemical yields during 4-[18F]fluorobenzoic acid ([18F]FBA) conjugation. Resin swelling was independently assessed using common SPPS solvents and SPPS performance was analyzed by comparing the post-synthesis yields of the notoriously difficult control peptide Val-Glu-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly (VQAAIDYING) under standard coupling conditions (3 eq amino acid, 3 eq HATU, 6 eq DIPEA, 1.5 hr, r.t.). The control peptide was then radiolabeled with [18F]FBA on amide and acid resins by employing a.) standard solid-phase coupling conditions (5 mg HATU, 10 [microliter] DIPEA, 30 min, r.t.) b.) heated reaction conditions (5 mg HATU, 10 [microliter] DIPEA, 30 min, 37°C) and c.) reduced coupling reagent equivalents (1.5-10 eq HATU, 3-44 eq DIPEA, 30 min, r.t.) in efforts to determine optimal solid-phase radiolabeling conditions and evaluate radiochemical yields and radiolabeling efficiency. Optimized conditions were tested through the synthesis of [18F]FBA-PEGA28-20FMDV2, a biologically relevant peptide which selectively targets the [alpha subscipt v][beta]6 integrin in vivo. Resins comprised exclusively of the polyethylene glycol polyacrylamide (PEGA) copolymer matrix exhibited the greatest swelling capacity and produced peptides with excellent purities (>87% ± 5.8%). Novasyn TGR, consisting of a polystyrene (PS) backbone cross-linked with polyethylene glycol (PEG), displayed poor swelling yet produced crude products with purities of 97.0 ± 2%. We also observed that Novasyn TGR exhibited the highest radiolabeling efficiency (86.1 ± 0.84%) between post-[18F]FBA conjugation and post-cleavage radiochemical yields, whereas the PEGA resins produced low radiochemical yields post-cleavage, which led to poor efficiencies (42.7 ± 0.96% Rink Amide PEGA, and 42.4 ± 0.86% HMPA PEGA). Heated [18F]FBA conjugation reactions enhanced efficiencies by 15.4% (Rink Amide PEGA) and by 25.9% (HMPA PEGA) while heated cleavage reactions increased efficiencies by 14.0% (Rink Amide PEGA) and 48.7% (HMPA PEGA). Additionally, reduction of the coupling reagent equivalents (6 eq HATU, 23 eq DIPEA) used during [18F]FBA conjugation improved efficiencies by 17.5% and 24.9% for Rink Amide PEGA and HMPA PEGA, respectively. When applied during [18F]FBA radiolabeling of the PEG28-A20FMDV2 peptide, the optimized conditions increased radiochemical yields by 23.2% on Rink Amide AM, 39.7% on Rink Amide PEGA, and by 131.8% on Novasyn TGR. This study successfully demonstrates the effects of solid supports during SPPS, in particular during [18F]FBA radiolabeling, and resulted in an optimized model for the synthesis of biologically relevant radiolabeled peptides in a reliable and efficient manner.

Bispecific Antibody Pretargeting for Improving Cancer Imaging and Therapy

Bispecific Antibody Pretargeting for Improving Cancer Imaging and Therapy
Author:
Publisher:
Total Pages: 6
Release: 2005
Genre:
ISBN:

The main objective of this project was to evaluate pretargeting systems that use a bispecific antibody (bsMAb) to improve the detection and treatment of cancer. A bsMAb has specificity to a tumor antigen, which is used to bind the tumor, while the other specificity is to a peptide that can be radiolabeled. Pretargeting is the process by which the unlabeled bsMAb is given first, and after a sufficient time (1-2 days) is given for it to localize in the tumor and clear from the blood, a small molecular weight radiolabeled peptide is given. According to a dynamic imaging study using a 99mTc-labeled peptide, the radiolabeled peptide localizes in the tumor in less than 1 hour, with> 80% of it clearing from the blood and body within this same time. Tumor/nontumor targeting ratios that are nearly 50 times better than that with a directly radiolabeled Fab fragment have been observed (Sharkey et al., ''Signal amplification in molecular imaging by a multivalent bispecific nanobody'' submitted). The bsMAbs used in this project have been composed of 3 antibodies that will target antigens found in colorectal and pancreatic cancers (CEA, CSAp, and MUC1). For the ''peptide binding moiety'' of the bsMAb, we initially examined an antibody directed to DOTA, but subsequently focused on another antibody directed against a novel compound, HSG (histamine-succinyl-glycine).

Radiotherapy in Practice - Radioisotope Therapy

Radiotherapy in Practice - Radioisotope Therapy
Author: Peter J Hoskin
Publisher: Oxford University Press
Total Pages: 200
Release: 2007-02-08
Genre: Medical
ISBN: 0198568428

Radioisotope therapy is an internal form of radiation, administered through liquid or injection, that treats cancer with minimal damage to the normal surrounding tissue. This book is a practical guide to radioisotope therapy, taking the reader through the basic principles, and then developing this by application to specific sites and diseases.

Handbook of In Vivo Chemistry in Mice

Handbook of In Vivo Chemistry in Mice
Author: Katsunori Tanaka
Publisher: John Wiley & Sons
Total Pages: 560
Release: 2020-04-27
Genre: Science
ISBN: 3527344322

Provides timely, comprehensive coverage of in vivo chemical reactions within live animals This handbook summarizes the interdisciplinary expertise of both chemists and biologists performing in vivo chemical reactions within live animals. By comparing and contrasting currently available chemical and biological techniques, it serves not just as a collection of the pioneering work done in animal-based studies, but also as a technical guide to help readers decide which tools are suitable and best for their experimental needs. The Handbook of In Vivo Chemistry in Mice: From Lab to Living System introduces readers to general information about live animal experiments and detection methods commonly used for these animal models. It focuses on chemistry-based techniques to develop selective in vivo targeting methodologies, as well as strategies for in vivo chemistry and drug release. Topics include: currently available mouse models; biocompatible fluorophores; radionuclides for radiodiagnosis/radiotherapy; live animal imaging techniques such as positron emission tomography (PET) imaging; magnetic resonance imaging (MRI); ultrasound imaging; hybrid imaging; biocompatible chemical reactions; ligand-directed nucleophilic substitution chemistry; biorthogonal prodrug release strategies; and various selective targeting strategies for live animals. -Completely covers current techniques of in vivo chemistry performed in live animals -Describes general information about commonly used live animal experiments and detection methods -Focuses on chemistry-based techniques to develop selective in vivo targeting methodologies, as well as strategies for in vivo chemistry and drug release -Places emphasis on material properties required for the development of appropriate compounds to be used for imaging and therapeutic purposes in preclinical applications Handbook of In Vivo Chemistry in Mice: From Lab to Living System will be of great interest to pharmaceutical chemists, life scientists, and organic chemists. It will also appeal to those working in the pharmaceutical and biotechnology industries.

Radiopharmaceutical Chemistry

Radiopharmaceutical Chemistry
Author: Jason S. Lewis
Publisher: Springer
Total Pages: 648
Release: 2019-04-02
Genre: Medical
ISBN: 3319989472

This book is a comprehensive guide to radiopharmaceutical chemistry. The stunning clinical successes of nuclear imaging and targeted radiotherapy have resulted in rapid growth in the field of radiopharmaceutical chemistry, an essential component of nuclear medicine and radiology. However, at this point, interest in the field outpaces the academic and educational infrastructure needed to train radiopharmaceutical chemists. For example, the vast majority of texts that address radiopharmaceutical chemistry do so only peripherally, focusing instead on nuclear chemistry (i.e. nuclear reactions in reactors), heavy element radiochemistry (i.e. the decomposition of radioactive waste), or solely on the clinical applications of radiopharmaceuticals (e.g. the use of PET tracers in oncology). This text fills that gap by focusing on the chemistry of radiopharmaceuticals, with key coverage of how that knowledge translates to the development of diagnostic and therapeutic radiopharmaceuticals for the clinic. The text is divided into three overarching sections: First Principles, Radiochemistry, and Special Topics. The first is a general overview covering fundamental and broad issues like “The Production of Radionuclides” and “Basics of Radiochemistry”. The second section is the main focus of the book. In this section, each chapter’s author will delve much deeper into the subject matter, covering both well established and state-of-the-art techniques in radiopharmaceutical chemistry. This section will be divided according to radionuclide and will include chapters on radiolabeling methods using all of the common nuclides employed in radiopharmaceuticals, including four chapters on the ubiquitously used fluorine-18 and a “Best of the Rest” chapter to cover emerging radionuclides. Finally, the third section of the book is dedicated to special topics with important information for radiochemists, including “Bioconjugation Methods,” “Click Chemistry in Radiochemistry”, and “Radiochemical Instrumentation.” This is an ideal educational guide for nuclear medicine physicians, radiologists, and radiopharmaceutical chemists, as well as residents and trainees in all of these areas.

99mTc-Sestamibi

99mTc-Sestamibi
Author: Jan Bucerius
Publisher: Springer Science & Business Media
Total Pages: 203
Release: 2011-09-22
Genre: Medical
ISBN: 3642042333

99mTc-sestamibi is a single-photon emission computed tomography (SPECT) radiotracer that is widely used for the imaging of myocardial perfusion, as well as a variety of malignant and benign diseases. 99mTc-Sestamibi – Clinical Applications provides a detailed and informative overview of almost all the oncologic and non-oncologic applications of 99mTc-sestamibi SPECT, including several relatively rare indications. Different disease-related protocols for 99mTc-sestamibi SPECT are presented, and for each disease a comprehensive summary of the relevant pathology and epidemiology is provided. Throughout, there is a strong emphasis on the practical aspects of use of this popular tracer, including instructions for the preparation of several commercially available tracer kits. Clinical practitioners will find this book to be an invaluable guide to the application and benefits of 99mTc-sestamibi SPECT in both the inpatient and the outpatient setting.